Most Recent Annual Report
Upgrade your company profile to unlock all of your annual report content on AnnualReports.com
2019 Form 10K
Relmada Therapeutics, Inc. has reached its limit for free report views.
Work for Relmada Therapeutics, Inc.?
Claim Your Profile
Relmada Therapeutics, Inc.
About Relmada Therapeutics, Inc.
1-10 Employees
Based in New York City, New York
Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines to address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, REL-1017 (dextromethadone) is an N-methyl-D-aspartate (NMDA) receptor antagonist in development for the treatment of depression. NMDA receptor antagonists may have utility in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.
- Ticker:
- RLMD
- Exchange:
- NASDAQ (See More NASDAQ Companies)
- Industry:
- Drug Manufacturers - Other (See More Drug Manufacturers - Other Companies)
- Sector:
- Healthcare (See More Healthcare Companies)
